Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination

Lorenza Bellusci; Gabrielle Grubbs; Fatema Tuz Zahra; David Forgacs; Hana Golding; Ted M. Ross; Surender Khurana

doi:10.1038/s41467-022-32298-w

Nature Communications (Aug 2022)

Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination

Lorenza Bellusci,
Gabrielle Grubbs,
Fatema Tuz Zahra,
David Forgacs,
Hana Golding,
Ted M. Ross,
Surender Khurana

Affiliations

Lorenza Bellusci: Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA
Gabrielle Grubbs: Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA
Fatema Tuz Zahra: Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA
David Forgacs: Center for Vaccines and Immunology, University of Georgia
Hana Golding: Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA
Ted M. Ross: Center for Vaccines and Immunology, University of Georgia
Surender Khurana: Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA

DOI: https://doi.org/10.1038/s41467-022-32298-w
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 9

Abstract

Read online

Here the authors show that a third SARS-CoV-2 vaccination significantly boosts neutralizing antibodies against Omicron subvariants and that hybrid immunity (infection and vaccination) results in broader neutralization activity and cross-reactive antibody affinity maturation.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal